Case-control study finds serum leptin predicts insulin resistance in obese type 2 diabetes patients, suggesting its metabolic risk utility.
The study demonstrated the clinical utility of serum leptin against IR in obese patients with T2DM but not in nonobese individuals, which suggested its potential utility as a metabolic risk biomarker.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: